Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Abstract Background Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substantially improved patients’ prognosis, drug resistance remains one of th...

Full description

Bibliographic Details
Main Authors: Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn, Ingolf Cascorbi
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Experimental Hematology & Oncology
Subjects:
CML
Imatinib
Chemoresistance
Leukemia
miR-142-5p
miR-365a-3p
Online Access:http://link.springer.com/article/10.1186/s40164-020-00183-1

Internet

http://link.springer.com/article/10.1186/s40164-020-00183-1

Similar Items